Cargando…

Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience

Immunoglobulin (Ig) D multiple myeloma (MM) accounts for 2% of all MM cases and has been reported to be associated with poor prognosis compared with other MM subtypes. The aim of the present study was to compare the effects of high-dose melphalan treatment and autologous stem cell transplantation (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Yong Pil, Kim, Shin, Ko, Ok Bae, Koo, Ja Eun, Lee, Danbi, Park, Sang Hyoung, Park, Soo Jung, Lee, Daeho, Kim, Sang We, Suh, Cheolwon
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2580008/ https://www.ncbi.nlm.nih.gov/pubmed/18955788 http://dx.doi.org/10.3346/jkms.2008.23.5.819

Ejemplares similares

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
por: Liu, Jin, et al.
Publicado: (2020)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Anaplastic morphology in IgD multiple myeloma
por: Roldán Galiacho, Verónica, et al.
Publicado: (2023)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

AL Amyloidosis in a Patient with IgD Myeloma
por: Rafik, Hicham, et al.
Publicado: (2020)

Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study
por: Ko, Ock Bae, et al.
Publicado: (2005)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

IgD myeloma/immunoblastic lymphoma cells expressing cytokeratin.
por: Sewell, H. F., et al.
Publicado: (1986)

IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis
por: Colombo, I., et al.
Publicado: (2010)

Aggressive FLC Escape in a Patient with IgD Myeloma
por: Farges, Cédric, et al.
Publicado: (2015)

Clinical characteristics and survival of patients with IgD multiple myeloma
por: Li, Yi, et al.
Publicado: (2021)

Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma
por: Wang, Wei, et al.
Publicado: (2018)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
por: De Santis, Elena, et al.
Publicado: (2016)

Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience
por: Jang, Il-Young, et al.
Publicado: (2014)

N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma
por: Chen, Jie, et al.
Publicado: (2017)

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
por: Kim, Min Kyoung, et al.
Publicado: (2017)

Physiology of IgD. IV. Enhancement of antibody production in mice bearing IgD-secreting plasmacytomas
Publicado: (1984)

IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion
por: Natori, Kazuhiko, et al.
Publicado: (2008)

Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma
por: Kishi, Seiji, et al.
Publicado: (2018)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Expression of IgD by murine lymphocytes. Loss of surface IgD indicates maturation of memory B cells
Publicado: (1978)

Physiology of IgD. VI. Transfer of the immunoaugmenting effect of IgD with T delta-containing helper cell populations
Publicado: (1985)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
por: Pisani, Francesco, et al.
Publicado: (2012)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
por: Husnain, Muhammad, et al.
Publicado: (2016)

Light chain deposition disease involving kidney and liver in a patient with IgD myeloma
por: Tsushima, Takafumi, et al.
Publicado: (2021)

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
por: Yan, Ge, et al.
Publicado: (2022)

Physiology of IgD. I. Compensatory phenomena in B lymphocyte activation in mice treated with anti-IgD antibodies
Publicado: (1981)

Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review
por: Chen, Zhongchuan W., et al.
Publicado: (2013)

IgD multiple myeloma with central nervous system involvement: A case report and literature review
por: Chen, Yi, et al.
Publicado: (2021)

Teleost IgD(+)IgM(−) B Cells Mount Clonally Expanded and Mildly Mutated Intestinal IgD Responses in the Absence of Lymphoid Follicles
por: Perdiguero, Pedro, et al.
Publicado: (2019)

Immunoglobulin D (IgD)-deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells
Publicado: (1993)

The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma
por: Roh, Jin, et al.
Publicado: (2017)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
por: Ursu, Sorana G., et al.
Publicado: (2023)

Differential Expression of IgM and IgD Discriminates Two Subpopulations of Human Circulating IgM(+)IgD(+)CD27(+) B Cells That Differ Phenotypically, Functionally, and Genetically
por: Bautista, Diana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2lublalkmos9uikm397vikucb8